Table 2.
Change in IOP (mmHg) from baseline to week 4 (worse eye, ANCOVA, PP population)
| Latanoprost concentration (μg/mL) | ||||
|---|---|---|---|---|
| |
50 |
75 |
100 |
125 |
| N |
69 |
66 |
71 |
68 |
|
8 a.m. IOP | ||||
| LS mean change (mmHg)* |
−10.13 |
−9.59 |
−10.02 |
−9.06 |
| Adjusted difference in LS mean ± SEM† |
|
0.54 ± 0.46 |
0.12 ± 0.45 |
1.07 ± 0.45 |
| (90% CI) |
|
(−0.22, 1.29) |
(−0.63, 0.86) |
(0.32, 1.82) |
| p-value‡ |
|
0.879 |
0.602 |
0.990 |
|
4 p.m. IOP | ||||
| LS mean change (mmHg)* |
−8.90 |
−8.29 |
−8.81 |
−8.34 |
| Adjusted difference in LS mean ± SEM† |
|
0.60 ± 0.47 |
0.09 ± 0.45 |
0.55 ± 0.46 |
| (90% CI) |
|
(−0.16, 1.37) |
(−0.67, 0.84) |
(−0.20, 1.31) |
| p-value‡ | 0.902 | 0.575 | 0.885 | |
ANCOVA analysis of covariance, CI confidence interval, IOP intraocular pressure, LS least square, PP per protocol, SEM standard error of the mean.
*Adjusting for baseline IOP (covariate) with dose group and center as factors.
†Higher concentration minus latanoprost 50 μg/mL; a negative difference in LS mean indicates that the higher concentration has a greater effect than latanoprost 50 μg/mL.
‡One-sided p-value.